Evaluation of allogeneic haematopoietic stem cell transplantation and pre- and post-transplant therapy in high-risk patients with chronic myeloid leukaemia

被引：0
|
作者：
Oyekunle, A. [1 ]
Klyuchnikov, E. [1 ]
Kroeger, N. [1 ]
Zabelina, T. [1 ]
Ayuk, F. [1 ]
Wolschke, C. [1 ]
Bernhardt, F. [1 ]
Mueller, I. [1 ]
Zander, A. [1 ]
Bacher, U. [1 ]
机构：
[1] Clin Stem Cell Transplantat, Hamburg, Germany
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S363 / S363
页数：1
相关论文
共 50 条
  • [41] Haploidentical haematopoietic stem cell transplantation is a valid option for patients with leukaemia in high-risk early or in intermediate disease status at transplant
    Aversa, F
    Terenzi, A
    Ballanti, S
    Tabilio, A
    Carotti, A
    Di Ianni, M
    Falzetti, F
    Aloisi, T
    Saab, J
    Santucci, A
    Martelli, F
    BONE MARROW TRANSPLANTATION, 2006, 37 : S251 - S252
  • [42] Voriconazole prophylaxis in 120 high-risk patients undergoing allogeneic haematopoietic stem cell transplantation
    Matteazzi, F.
    Clerici, D.
    Greco, R.
    Marcatti, M.
    Fumagalli, L.
    Peccatori, J.
    Bernardi, M.
    Ciceri, F.
    Corti, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S221 - S222
  • [43] Evaluation of Post-Transplant Iron Chelation Therapy in Allogeneic Hematopoietic Stem Cell Transplant
    Aziz, May
    Gregory, Kelly
    Corrigan, Patricia
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S376 - S376
  • [44] SUCCESSFUL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR HIGH-RISK PAEDIATRIC ACUTE MYELOID LEUKAEMIA USING CHEMOTHERAPY-ONLY CONDITIONING AND POST TRANSPLANT IMMUNOTHERAPY
    Bonanomi, S.
    Connor, P.
    Webb, D.
    Ancliff, P.
    Persis, A.
    Rao, K.
    McCloskey, D.
    Hemmatpour, S.
    Goulden, N.
    Veys, P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 79 - 79
  • [45] Haematopoietic stem cell transplantation for patients with chronic myeloid leukaemia after failure of tyrosine kinase inhibitor therapy
    Prayongratana, K.
    Forrest, D.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S428 - S429
  • [46] Allogeneic stem cell transplantation in patients with chronic myeloid leukaemia: application of the EBMT risk scoring system
    Novella, E
    Madeo, D
    Raimondi, R
    Cappellari, A
    Guercini, N
    Montaldi, AM
    Roberti, S
    Rodeghiero, F
    BONE MARROW TRANSPLANTATION, 2005, 35 : S235 - S235
  • [47] B LYMPHOCYTE RECONSTITUTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR HAEMATOLOGICAL DISORDERS: CORRELATION WITH PRE- AND POST-TRANSPLANT FACTORS
    Richardson, D. S.
    Hodges, E.
    Mani, A.
    Hurlock, C.
    Newman, J.
    McKeag, N.
    Hill, K.
    Orchard, K. H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 144 - 144
  • [48] Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Giralt, Sergio A.
    Arora, Mukta
    Goldman, John M.
    Lee, Stephanie J.
    Maziarz, Richard T.
    McCarthy, Philip L.
    Sobocinski, Kathleen A.
    Horowitz, Mary M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) : 461 - 467
  • [49] Post-Transplant Immune Monitoring In Patients Receiving Allogeneic Stem Cell Transplantation
    Park, Silvia
    Jung, Chul Won
    Jang, Jun Ho
    Kang, Eun Suk
    Kim, Kihyun
    BLOOD, 2013, 122 (21)
  • [50] Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
    Edahiro, Taro
    Ureshino, Hiroshi
    Chishaki, Ren
    Fujino, Keita
    Mino, Tatsuji
    Yoshida, Tetsumi
    Fukushima, Noriyasu
    Ichinohe, Tatsuo
    INTERNAL MEDICINE, 2023, 62 (15) : 2243 - 2247
12345